...
首页> 外文期刊>ESHRE Monographs >Intrauterine insemination (IUI) as a first-line treatment in developing countries and methodological aspects that might influence IUI success
【24h】

Intrauterine insemination (IUI) as a first-line treatment in developing countries and methodological aspects that might influence IUI success

机译:宫腔内人工授精(IUI)作为发展中国家的一线治疗和可能影响IUI成功的方法学方面

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

It is generally accepted that intrauterine insemination (IUI) should be preferred to more invasive and expensive techniques of assisted reproduction and be offered as a first-choice treatment in cases of unexplained and moderate male factor subfertility. Scientific validation of this strategy is rather difficult because literature is rather confusing and not conclusive. IUI is proven easier to perform, less invasive and less expensive than other methods of assisted reproduction. Effectivity has been documented in controlled studies under the condition that the inseminating motile count exceeds more than 1 million motile spermatozoa. Risks are minimal, provided the multiple gestation incidence can be reduced to an acceptable level and provided at least one tube is patent. Therefore, in developing countries, reflection on the implementation and use of IUI as a first-line treatment for most cases of non-tubal infertility seems mandatory. The costs are minimal, training is easy, quality control possible and severe complications are almost non-existing. In cases of unexplained infertility or combined male subfertility and ovulatory dysfunction, correction and/or ovarian stimulation with clomiphene citrate (CC) is probably the best strategy from a cost–benefit point of view unless CC-resistancy has been proven in which the use of low-dose gonadotrophins is necessary.
机译:人们普遍认为,宫腔内人工授精(IUI)应优于更具侵入性和昂贵的辅助生殖技术,并在无法解释的中度男性因素不孕的情况下作为首选治疗方法。对这一策略进行科学验证是相当困难的,因为文献令人迷惑而不是结论性的。事实证明,与其他辅助复制方法相比,IUI易于执行,侵入性较低且成本较低。在授精运动计数超过一百万个运动精子的条件下,在对照研究中已证明有效果。如果可以将多胎妊娠的发生率降低到可接受的水平,并且至少一根输卵管是有专利的,则风险是最小的。因此,在发展中国家,对大多数非输卵管性不育病例的IUI的实施和使用进行反思是必须的。成本最低,培训容易,可以进行质量控制,几乎不存在严重的并发症。对于无法解释的不育症或男性不育症和排卵功能障碍的合并症,从成本效益的角度出发,用柠檬酸克罗米芬(CC)进行矫正和/或卵巢刺激可能是最好的策略,除非已证明使用CC耐药性低剂量促性腺激素是必要的。

著录项

  • 来源
    《ESHRE Monographs》 |2008年第1期|p.64-72|共9页
  • 作者单位

    1Genk Institute for Fertility Technologies, Department of Obstetrics and Gynaecology, Ziekenhuizen Oost-Limburg, Schiepse Bos 2, 3600 Genk, Belgium 2Flemish Society of Obstetrics and Gynaecology, Belgium 3Leuven Institute for Fertility and Embryology, Leuven, Belgium;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号